Access optionsAccess options
Subscribe to Journal
Get full journal access for 1 year
only $102.00 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Roboz GJ . Current treatment of acute myeloid leukemia. Curr Opin Oncol 2012; 24: 711–719.
Paschka P . Core binding factor acute myeloid leukemia. Semin Oncol 2008; 35: 410–417.
Sinha C, Cunningham LC, Liu PP . Core binding factor acute myeloid leukemia: new prognostic categories and therapeutic opportunities. Semin Hematol 2015; 52: 215–222.
Hatlen MA, Wang L, Nimer SD . AML1-ETO driven acute leukemia: insights into pathogenesis and potential therapeutic approaches. Front Med 2012; 6: 248–262.
Bessette DC, Qiu D, Pallen CJ . PRL PTPs: mediators and markers of cancer progression. Cancer Metast Rev 2008; 27: 231–252.
Kobayashi M, Chen S, Gao R, Bai Y, Zhang ZY, Liu Y . Phosphatase of regenerating liver in hematopoietic stem cells and hematological malignancies. Cell Cycle 2014; 13: 2827–2835.
Zhou J, Bi C, Chng WJ, Cheong LL, Liu SC, Mahara S et al. PRL-3, a metastasis associated tyrosine phosphatase, is involved in FLT3-ITD signaling and implicated in anti-AML therapy. PLoS One 2011; 6: e19798.
Kobayashi M, Bai Y, Dong Y, Yu H, Chen S, Gao R et al. PRL2/PTP4A2 phosphatase is important for hematopoietic stem cell self-renewal. Stem Cells 2014; 32: 1956–1967.
Kobayashi M, Nabinger SC, Bai Y, Yoshimoto M, Gao R, Chen S et al. Protein tyrosine phosphatase PRL2 mediates notch and kit signals in early T cell progenitors. Stem Cells 2016; e-pub ahead of print 23 December 2016 doi:10.1002/stem.2559.
Kobayashi M, Bai Y, Chen S, Gao R, Yao C, Cai W et al. Phosphatase PRL2 promotes oncogenic NOTCH1-induced T cell leukemia. Leukemia 2017; 31: 751–754.
Bagger FO, Rapin N, Theilgaard-Mönch K, Kaczkowski B, Jendholm J, Winther O et al. HemaExplorer: a Web server for easy and fast visualization of gene expression in normal and malignant hematopoiesis. Blood 2012; 119: 6394–6395.
Bai Y, Yu ZH, Liu S, Zhang L, Zhang RY, Zeng LF et al. Novel anticancer agents based on targeting the trimer interface of the PRL phosphatase. Cancer Res 2016; 76: 4805–4815.
Mulloy JC, Cammenga J, MacKenzie KL, Berguido FJ, Moore MA, Nimer SD . The AML1-ETO fusion protein promotes the expansion of human hematopoietic stem cells. Blood 2002; 99: 15–23.
Yuan Y, Zhou L, Miyamoto T, Iwasaki H, Harakawa N, Hetherington CJ et al. AML1-ETO expression is directly involved in the development of acute myeloid leukemia in the presence of additional mutations. Proc Natl Acad Sci USA 2001; 98: 10398–10403.
Yan M, Kanbe E, Peterson LF, Boyapati A, Miao Y, Wang Y et al. A previously unidentified alternatively spliced isoform of t(8;21) transcript promotes leukemogenesis. Nat Med 2006; 12: 945–949.
Sun XJ, Wang Z, Wang L, Jiang Y, Kost N, Soong TD et al. A stable transcription factor complex nucleated by oligomeric AML1-ETO controls leukaemogenesis. Nature 2013; 500: 93–97.
This work was supported, in part, by National Institutes of Health Grant CA69202 (to ZYZ), Department of Defense Grant W81XWH-13-1-0187 (to YL), a St Baldrick’s Foundation Scholar Award (to YL), an Elsa Pardee Foundation New Investigator Award (to YL), an Alex’s Lemonade Stand Foundation Grant (to YL), a Children’s Leukemia Research Association Grant (to YL), a Leukemia Research Foundation grant (to YL) and American Cancer Society Institutional Research Grants (to YL and MK). This work was supported by a Project Development Team within the ICTSI NIH/NCRR Grant Number UL1TR001108. We also thank Marilyn Wales and John Spence for helping the preparation of the manuscript.
MK, SC, YB, ZYZ and YL: designed the research. MK, SC, YB, CY, RG, XJS, CM, TAT and ZHY: performed the research; MK and YL: analyzed the data and performed the statistical analysis. HSB, MCY, RK and JCM: provided reagents to the study. ZYZ and YL: wrote the manuscript. All authors read, commented on and approved the manuscript.
The authors declare no conflict of interest.
Supplementary Information accompanies this paper on the Leukemia website
About this article
The FEBS Journal (2018)